Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences mai 12, 2025 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2025 Operating and Financial Results mai 08, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference mai 02, 2025 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 mai 01, 2025 at 12:00 PM UTC
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth avril 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results mars 13, 2025 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets décembre 08, 2023 at 12:30 PM UTC
Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results novembre 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing novembre 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference septembre 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets septembre 27, 2023 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference septembre 07, 2023 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results août 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets août 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit juillet 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results mai 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 mai 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May avril 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 avril 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event mars 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing mars 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences mars 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 février 28, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index décembre 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 décembre 18, 2018 at 03:27 PM UTC